[Clinical examination of mizolastine in the seasonal allergic rhinitis].
An open randomized comparative study versus loratadine was conducted in order to examine the efficacy and safety of mizolastine in the treatment of seasonal allergic rhinitis (SAR). Six-seven adult patients completed mizolastine 10 mg (34/67) and loratadine 10 mg (33/67) once daily for 14 days. Other 5 patients withdrew or dropped out from the trial. All symptom score decreased significantly after treatment in both groups. Efficacy assessment based on symptom score reducing index showed that the efficacy of Mizolastine was 82.4%, and the excellent rate was 20.6%, while the efficacy of Loratadine was 66.7%, and the excellent rate was 6.1%. No serious adverse events were reported in the two groups. The incidences of adverse drug reactions (ADRs) of Mizolastine and Loratadine were 38.2% and 33.3% respectively. The mild or moderate drowsiness and dry mouth in Mizolastine group were 26.5% and 8.8% respectively, and in Loratadine group they were 18.2% and 9.0%. There were no significant changes in laboratory examinations including blood and urine routine tests, liver and renal functions and ECG. Mizolastine is effective in relieving SAR symptoms. The efficacy and ADR of mizolastine is similar to Loratadine in the treatment of SAR.